- Home
- KNSA vs HCM Comparison
KNSA vs HCM Comparison
Compare KNSA & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNSA | HCM |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United Kingdom | Hong Kong |
| Employees | N/A | 1811 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.4B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | KNSA | HCM |
|---|---|---|
| Price | $45.36 | $14.24 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 7 | 1 |
| Target Price | ★ $55.29 | $13.75 |
| AVG Volume (30 Days) | ★ 599.1K | 19.7K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 225.00 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $677,564,000.00 | N/A |
| Revenue This Year | $38.01 | $28.37 |
| Revenue Next Year | $17.42 | $17.50 |
| P/E Ratio | $61.55 | ★ $5.49 |
| Revenue Growth | ★ 60.09 | N/A |
| 52 Week Low | $18.26 | $11.51 |
| 52 Week High | $49.12 | $19.50 |
Technical Indicators
Market Signals| Indicator | KNSA | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 50.68 | 43.74 |
| Support Level | $40.47 | $13.09 |
| Resistance Level | $46.48 | $15.49 |
| Average True Range (ATR) | 2.12 | 0.44 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 66.72 | 42.06 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.